{"acquisitions":[],"changes":[],"country":"FR","description":"Hephaistos-Pharma develops a third-generation TLR4-agonist small molecule for cancer immunotherapy, with lead candidate HEPHA440 reprogramming suppressive myeloid cells and activating immune responses. It targets oncology patients with myeloid-rich tumors resistant to current immunotherapies. It aims to turn immunologically cold tumors hot via a dual innate-and-adaptive mechanism.","domain":"hephaistos-pharma.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":48.708795,"lng":2.174818,"location":"Orsay","multiples":[],"name":"Hephaistos-Pharma","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2700000,"connectionsAmong":[],"currency":"EUR","date":"2023-07-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"hephaistos-pharma-com-2023-07-01-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"hephaistos-pharma-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"hephaistos-pharma.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://hephaistos-pharma.com"},{"fact":"description","publisher":"hephaistos-pharma.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://hephaistos-pharma.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["PHP 8.2.29","WordPress 6.9.4","Apache HTTP Server","Google Maps","FitVids.JS 4.27.4","jQuery Migrate 3.4.1","CookieYes 3.5.0","Varnish 6.3","Zepto","MySQL","jquery 3.","apache"],"totalRaisedUsd":2700000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}